$ALMS

Pangali Sanam sold $36K of ALMS

Pangali Sanam (Chief Legal Officer) sold 1,364 shares of ALUMIS INC. (ALMS) at $26.37 on 2026-08-03.

Original reporting
SEC EDGAR · Pangali Sanam
Published Aug 5, 2026, 10:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALMS
Neutral
low confidence
Mentioned
$ALMS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale size, price, and post-transaction holdings, with no 10b5-1 plan indicated.

02

Market read

Traders may note insider selling for sentiment, but there is no new guidance, contract, or regulatory development in the text.

03

What to watch

The article does not state whether the sale was part of broader planned selling, nor does it provide context on total holdings, compensation, or prior sale patterns.

Relevance 3/10Novelty 3/10Timing: Filed on 2026-08-05 after-hours; reflects sale executed 2026-08-03.

Background

The filing is an SEC Form 4 insider transaction for ALUMIS INC. (ALMS) by its Chief Legal Officer, Pangali Sanam.

Company-level read

Ticker impact

$ALMSNeutralLow confidence
Context

ALMS insider Pangali Sanam sold 1,364 shares on 2026-08-03 at $26.3700, disclosing $35,968.68 in proceeds.

Expected impact

Likely limited near-term impact; any effect would be short-lived unless paired with other company-specific news.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the filing provides transaction details but no new operational or financial guidance.

Market effects

No clear sector read-through from a single insider sale without additional company or industry disclosures.

None indicated.

None indicated.

Counterpoint

The sale may be for personal liquidity or tax planning and does not necessarily signal reduced confidence, especially without any accompanying negative company news.

Key entities

  • ALUMIS INC.

    Company whose insider transaction is disclosed on Form 4.

  • Pangali Sanam

    Chief Legal Officer who sold 1,364 shares of ALMS.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALMSMed

Why is Alumis stock rallying today?

Alumis (ALMS) stock rose 6.3% in pre-market trading after presenting long-term skin-clearance data for envudeucitinib at the Cantor Fitzgerald Global Healthcare Conference. Management highlighted potential partnerships and insider Srinivas Akkaraju bought 986,000 shares. The FDA application for envudeucitinib is expected in Q4 2026.

$ALMSMedAI 8/10

Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population

Alumis Inc. (ALMS) reported that its Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus did not meet primary or secondary endpoints in the overall population. However, a prespecified subgroup with high interferon gene signature showed numerically higher responses. The company plans to discuss Phase 3 trial design with regulators. Envudeucitinib was generally well tolerated.

$ALMSMedAI 8/10

Alumis Phase 2b LUMUS Trial Misses Endpoints; Stock Plunges

Alumis Inc. (ALMS) reported Phase 2b LUMUS trial results for Envudeucitinib in SLE, missing primary and secondary endpoints overall but showing promise in a subset of patients with high interferon gene signature. The drug demonstrated improvements in several measures in this subgroup and was well tolerated. The company plans to discuss Phase 3 development with regulators. ALMS stock fell over 55% in pre-market trading.